Aurinia Pharmaceuticals v. Galenicum Health: LUPKYNIS Patent Infringement — Consolidated
Aurinia Pharmaceuticals asserted two voclosporin patents covering its LUPKYNIS drug against Spanish generic challenger Galenicum Health in New Jersey federal court. Within 230 days of filing, the court consolidated this action with a related case for all pre-trial purposes, designating Civil Action No. 25-2580 as the lead proceeding.
LUPKYNIS voclosporin patents draw NJ consolidation order against Galenicum
On April 17, 2025, Aurinia Pharmaceuticals, Inc. filed Civil Action No. 2:25-cv-02807 in the District of New Jersey against Galenicum Health S.L.U., a Spanish pharmaceutical company, asserting infringement of US11622991B2 and US10286036B2 — two patents covering the voclosporin drug marketed as LUPKYNIS, Aurinia’s calcineurin inhibitor approved for lupus nephritis. The action is consistent with a Hatch-Waxman ANDA litigation pattern, suggesting Galenicum filed an Abbreviated New Drug Application seeking to market a generic voclosporin product.
On December 3, 2025, the court entered a consolidation order under Federal Rule of Civil Procedure 42 and Local Civil Rule 42.1, merging this action with a related case into a single consolidated proceeding. Civil Action No. 25-2580 was designated the lead case, and all future filings are to be made exclusively in that docket. The order was entered without opposition from any party, suggesting coordinated case management rather than a contested procedural dispute.
The consolidation occurred 230 days after filing — a relatively swift administrative resolution for multi-action pharmaceutical patent litigation. The unopposed nature of the order suggests the parties agreed that the related actions share common questions of law or fact, most likely arising from the same ANDA filing or the same asserted patents. The merits of Galenicum’s invalidity or non-infringement positions remain entirely unresolved in the public record, and substantive litigation now proceeds under the lead docket 25-2580.
Filing to Case Consolidated in 230 days
230 days from filing to consolidation order — typical for early-stage ANDA/Hatch-Waxman coordination
What consolidation means: this case merges into lead action 25-2580
Rule 42 consolidation — one proceeding, multiple actions
Under Federal Rule of Civil Procedure 42(a), courts may consolidate actions sharing common questions of law or fact. Here, the court found that this case and the related action (25-2580) meet that threshold. Consolidation does not terminate or decide the underlying infringement claims — it reorganises them into a single docket to avoid duplicative discovery and inconsistent rulings. The substantive patent fight continues.
Procedural consolidationLead case 25-2580 now controls all filings
Effective December 3, 2025, all filings in the consolidated proceeding must be made in Civil Action No. 25-2580. This case (2:25-cv-02807) is administratively closed as a standalone docket but its claims survive within the consolidated action. Practitioners monitoring this dispute should redirect their docket tracking to the lead case number to follow discovery, claim construction, and any trial scheduling.
Track docket 25-2580Plaintiff gains coordinated enforcement across related actions
Consolidation benefits Aurinia by allowing it to prosecute its voclosporin patent portfolio in a single, coordinated proceeding. Shared discovery and unified case management reduce duplication and litigation cost. The two asserted patents — US11622991B2 and US10286036B2 — remain fully in play, and Aurinia retains all enforcement rights against Galenicum within the lead case.
Enforcement continuesGeneric challenger faces consolidated defence burden
For Galenicum, consolidation means its invalidity or non-infringement arguments will be litigated alongside related defendants or actions in a single forum. While consolidation can create efficiencies, it also concentrates litigation risk. Galenicum’s path to market for any generic voclosporin product remains blocked by the 30-month Hatch-Waxman stay, presuming standard ANDA litigation timelines apply.
Generic launch delayedFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Aurinia Pharmaceuticals, Inc. | Company | Biopharmaceutical company — holder of US11622991B2 and US10286036B2 covering voclosporinSearch in Eureka ↗ |
| Defendant | GALENICUM HEALTH S.L.U. | Individual | Galenicum Health S.L.U. — Spanish generic pharmaceutical manufacturerSearch in Eureka ↗ |
| Plaintiff counsel | C. COLLETTE CORSER | Attorney | Counsel for Aurinia Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | DANIELLE A. DUSZCZYSZYN | Attorney | Counsel for Aurinia Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | EMILY R. GABRANSKI | Attorney | Counsel for Aurinia Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | EMMA CAPITANELLI | Attorney | Counsel for Aurinia Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | J. BRUGH LOWER | Attorney | Counsel for Aurinia Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | JUSTIN SILVERBERG | Attorney | Counsel for Aurinia Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | MARK FELDSTEIN | Attorney | Counsel for Aurinia Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | RYAN V. MCDONNELL | Attorney | Counsel for Aurinia Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | William P. Deni , Jr. | Attorney | Counsel for Aurinia Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Gibbons PC | Law Firm | Representing Aurinia Pharmaceuticals, Inc.Search in Eureka ↗ |
| Defendant counsel | Eric I. Abraham | Attorney | Counsel for GALENICUM HEALTH S.L.U.Search in Eureka ↗ |
| Defendant counsel | Kristine L. Butler | Attorney | Counsel for GALENICUM HEALTH S.L.U.Search in Eureka ↗ |
| Defendant counsel | William Murtha | Attorney | Counsel for GALENICUM HEALTH S.L.U.Search in Eureka ↗ |
| Defendant law firm | Hill Wallack LLP | Law Firm | Representing GALENICUM HEALTH S.L.U.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | New Jersey District CourtSearch in Eureka ↗ |
Official order — verbatim text
The December 3, 2025 order is purely procedural — it consolidates parallel infringement actions under a single lead docket and makes no merits determination on validity or infringement of either asserted patent. The court’s finding of ‘common questions of law or fact’ under Rule 42(a) and the absence of any party opposition together suggest coordinated case management in what is consistent with multi-defendant Hatch-Waxman litigation. No damages, injunctions, or claim constructions have been issued. All substantive rights of both parties remain intact in the lead proceeding.
US11622991B2 & US10286036B2 — voclosporin (LUPKYNIS) pharmaceutical patents
US11622991B2 (application US17/713140) and US10286036B2 (application US15/835219) both relate to voclosporin, a novel calcineurin inhibitor commercialised by Aurinia as LUPKYNIS — the first FDA-approved oral treatment specifically for lupus nephritis. The patents are expected to cover aspects of the formulation, dosing regimens, or therapeutic methods associated with voclosporin, providing Aurinia with a multi-layered exclusivity position on its lead commercial product. The different application dates suggest these patents protect distinct aspects of the voclosporin programme, from early composition work to later clinical formulation refinements.
LUPKYNIS generated significant commercial interest as the first calcineurin inhibitor approved for lupus nephritis in the United States, making its patent estate a high-value enforcement target. The assertion of two patents in parallel against a generic filer is consistent with Aurinia’s Orange Book listing strategy and its intent to maximise the 30-month Hatch-Waxman stay period. Any company developing voclosporin generics, biosimilar-adjacent calcineurin inhibitors, or competing lupus nephritis therapies should treat both patents as active infringement risk vectors until the consolidated litigation resolves.
Should you run an FTO against US11622991B2 and US10286036B2?
If your organisation is developing a voclosporin generic, a cyclosporine-derivative calcineurin inhibitor, or any oral immunosuppressant formulation targeting lupus nephritis or related autoimmune indications, both asserted patents represent live freedom-to-operate concerns. The active consolidated litigation in New Jersey confirms Aurinia is actively enforcing these patents. R&D and regulatory teams should assess claim scope before committing to formulation strategies or ANDA filings.
PatSnap Eureka’s FTO Search Agent can map the independent and dependent claims of US11622991B2 and US10286036B2 against your product profile, identify relevant prior art that Galenicum may be leveraging in its invalidity case, and flag related Aurinia patent families that may not yet be Orange Book-listed. Use Eureka to build a defensible FTO opinion before your next regulatory milestone.
Run a freedom-to-operate analysis on US11622991B2 to assess your product’s exposure
Run FTO in Eureka →Similar Hatch-Waxman voclosporin and calcineurin inhibitor patent cases
Explore related ANDA patent infringement actions in the NJ District Court involving calcineurin inhibitors, lupus nephritis drug patents, and multi-defendant Hatch-Waxman consolidations.
What this case signals for the voclosporin and calcineurin inhibitor IP landscape
Aurinia’s multi-front enforcement of LUPKYNIS patents signals a robust exclusivity defence strategy in the lupus nephritis market.
Multi-action consolidation signals coordinated generic entry challenge
The existence of at least two related cases consolidated on the same docket suggests multiple ANDA filers are targeting voclosporin simultaneously. This is a common pattern in high-value pharmaceutical IP disputes where the brand holder files separate suits against each generic applicant, then seeks consolidation for efficiency. Competitors should monitor all co-pending actions under lead docket 25-2580.
Two asserted patents extend voclosporin exclusivity beyond single-patent exposure
Aurinia has asserted both US11622991B2 and US10286036B2, suggesting a layered patent strategy covering voclosporin formulations and methods of treatment. Generic challengers must successfully invalidate or design around both patents to obtain clearance. This stacking approach is consistent with Hatch-Waxman lifecycle management and raises the bar for any ANDA filer seeking early market entry.
Aurinia v GALENICUM — key questions answered
The case was consolidated on December 3, 2025 into lead action Civil Action No. 25-2580. Aurinia filed the suit on April 17, 2025, asserting infringement of US11622991B2 and US10286036B2 covering its LUPKYNIS voclosporin drug. No merits determination was made — the consolidation order was procedural and unopposed.
Aurinia asserted two patents: US11622991B2 (application US17/713140) and US10286036B2 (application US15/835219), both relating to voclosporin formulations and therapeutic uses underlying the LUPKYNIS drug approved for lupus nephritis.
Consolidation under Federal Rule of Civil Procedure 42(a) merges this action with Civil Action No. 25-2580 for all pre-trial purposes including discovery and case management. The underlying patent infringement claims remain active — consolidation is a procedural step, not a merits ruling. All future filings are made in the lead docket 25-2580.
The public record does not expressly confirm an ANDA filing, but the case pattern — a branded pharmaceutical company asserting Orange Book-listed patents against a generic manufacturer in NJ District Court — is consistent with Hatch-Waxman paragraph IV certification litigation. The product involved is LUPKYNIS (voclosporin), and consolidation with a related action further suggests multiple generic ANDA filers.
Following the December 3, 2025 consolidation order, Civil Action No. 25-2580 in the District of New Jersey is the lead case. All filings in the consolidated proceeding, including this case (2:25-cv-02807), are to be made exclusively in that docket going forward.
PatSnap Eureka searches patents and litigation data to answer instantly.